Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome.

Echevarria MI, Awasthi S, Cheng CH, Berglund AE, Rounbehler RJ, Gerke TA, Takhar M, Davicioni E, Klein EA, Freedland SJ, Ross AE, Schaeffer EM, Den RB, Cleveland JL, Park JY, Rayford W, Yamoah K.

J Urol. 2019 Feb 15:101097JU0000000000000193. doi: 10.1097/JU.0000000000000193. [Epub ahead of print]

PMID:
31107158
2.

epiTAD: a web application for visualizing chromosome conformation capture data in the context of genetic epidemiology.

Creed JH, Aden-Buie G, Monteiro AN, Gerke TA.

Bioinformatics. 2019 May 17. pii: btz387. doi: 10.1093/bioinformatics/btz387. [Epub ahead of print]

PMID:
31099399
3.

Aneuploidy drives lethal progression in prostate cancer.

Stopsack KH, Whittaker CA, Gerke TA, Loda M, Kantoff PW, Mucci LA, Amon A.

Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11390-11395. doi: 10.1073/pnas.1902645116. Epub 2019 May 13.

PMID:
31085648
4.

A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2).

Mazzu YZ, Armenia J, Chakraborty G, Yoshikawa Y, Coggins SA, Nandakumar S, Gerke TA, Pomerantz MM, Qiu X, Zhao H, Atiq M, Khan N, Komura K, Lee GM, Fine SW, Bell C, O'Connor E, Long HW, Freedman ML, Kim B, Kantoff PW.

Clin Cancer Res. 2019 Apr 17. doi: 10.1158/1078-0432.CCR-18-4046. [Epub ahead of print]

PMID:
30996073
5.

Pre-orchiectomy tumor marker levels should not be used for International Germ Cell Consensus Classification (IGCCCG) risk group assignment.

Fankhauser CD, Gerke TA, Roth L, Sander S, Grossmann NC, Kranzbühler B, Eberli D, Sulser T, Beyer J, Hermanns T.

J Cancer Res Clin Oncol. 2019 Mar;145(3):781-785. doi: 10.1007/s00432-019-02844-z. Epub 2019 Jan 14.

PMID:
30637464
6.

Identification of jointly correlated gene sets.

Ren Y, Ay A, Gerke TA, Kahveci T.

J Bioinform Comput Biol. 2018 Oct;16(5):1840019. doi: 10.1142/S021972001840019X.

PMID:
30419787
7.

BMI trajectories and risk of overall and grade-specific prostate cancer: An observational cohort study among men seen for prostatic conditions.

Wang K, Chen X, Gerke TA, Bird VY, Ghayee HK, Prosperi M.

Cancer Med. 2018 Oct;7(10):5272-5280. doi: 10.1002/cam4.1747. Epub 2018 Sep 11.

8.

Regular aspirin use and gene expression profiles in prostate cancer patients.

Stopsack KH, Ebot EM, Downer MK, Gerke TA, Rider JR, Kantoff PW, Mucci LA.

Cancer Causes Control. 2018 Aug;29(8):775-784. doi: 10.1007/s10552-018-1049-5. Epub 2018 Jun 18.

PMID:
29915914
9.

ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D.

Komura K, Yoshikawa Y, Shimamura T, Chakraborty G, Gerke TA, Hinohara K, Chadalavada K, Jeong SH, Armenia J, Du SY, Mazzu YZ, Taniguchi K, Ibuki N, Meyer CA, Nanjangud GJ, Inamoto T, Lee GM, Mucci LA, Azuma H, Sweeney CJ, Kantoff PW.

J Clin Invest. 2018 Jul 2;128(7):2979-2995. doi: 10.1172/JCI96769. Epub 2018 Jun 4.

10.

Toenail selenium, genetic variation in selenoenzymes and risk and outcome in glioma.

Peeri NC, Creed JH, Anic GM, Thompson RC, Olson JJ, LaRocca RV, Chowdhary SA, Brockman JD, Gerke TA, Nabors LB, Egan KM.

Cancer Epidemiol. 2018 Aug;55:45-51. doi: 10.1016/j.canep.2018.05.002. Epub 2018 May 25.

PMID:
29777993
11.

Association between age-related reductions in testosterone and risk of prostate cancer-An analysis of patients' data with prostatic diseases.

Wang K, Chen X, Bird VY, Gerke TA, Manini TM, Prosperi M.

Int J Cancer. 2017 Nov 1;141(9):1783-1793. doi: 10.1002/ijc.30882. Epub 2017 Jul 24.

12.

Cholesterol uptake and regulation in high-grade and lethal prostate cancers.

Stopsack KH, Gerke TA, Andrén O, Andersson SO, Giovannucci EL, Mucci LA, Rider JR.

Carcinogenesis. 2017 Aug 1;38(8):806-811. doi: 10.1093/carcin/bgx058.

13.

Re: Won Sik Ham, Heather J. Chalfin, Zhaoyong Feng, et al. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer. Eur Urol 2017;71:907-12.

Fankhauser CD, Mucci LA, Gerke TA.

Eur Urol. 2017 Jul;72(1):e9-e10. doi: 10.1016/j.eururo.2017.01.016. Epub 2017 Jan 17. No abstract available.

14.

Perineural Invasion and Risk of Lethal Prostate Cancer.

Zareba P, Flavin R, Isikbay M, Rider JR, Gerke TA, Finn S, Pettersson A, Giunchi F, Unger RH, Tinianow AM, Andersson SO, Andrén O, Fall K, Fiorentino M, Mucci LA; Transdisciplinary Prostate Cancer Partnership (ToPCaP).

Cancer Epidemiol Biomarkers Prev. 2017 May;26(5):719-726. doi: 10.1158/1055-9965.EPI-16-0237. Epub 2017 Jan 6.

15.

Cholesterol Metabolism and Prostate Cancer Lethality.

Stopsack KH, Gerke TA, Sinnott JA, Penney KL, Tyekucheva S, Sesso HD, Andersson SO, Andrén O, Cerhan JR, Giovannucci EL, Mucci LA, Rider JR.

Cancer Res. 2016 Aug 15;76(16):4785-90. doi: 10.1158/0008-5472.CAN-16-0903. Epub 2016 Jun 20.

16.

Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUC.

Gerke TA, Martin NE, Ding Z, Nuttall EJ, Stack EC, Giovannucci E, Lis RT, Stampfer MJ, Kantoff PW, Parmigiani G, Loda M, Mucci LA.

Prostate. 2015 Dec;75(16):1926-33. doi: 10.1002/pros.23090. Epub 2015 Sep 7.

Supplemental Content

Loading ...
Support Center